Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : UB-612
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Inapplicable
December 22, 2021
Lead Product(s) : UB-612
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : UB-612
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Sponsor : Vaxxinity
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Inapplicable
July 20, 2021
Lead Product(s) : UB-612
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Sponsor : Vaxxinity
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : UB-612
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : Vaxxinity
Deal Size : Inapplicable
Deal Type : Inapplicable
A Study to Evaluate UB-612 COVID-19 Vaccine in Adolescent, Younger and Elderly Adult Volunteers
Details : Undisclosed
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Inapplicable
February 26, 2021
Lead Product(s) : UB-612
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : Vaxxinity
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : UB-612
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Recipient : Vaxxinity
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Taiwan Ministry of Health and Welfare on January 29, granted conditional approval to begin Phase 2 trials of UB-612, its vaccine candidate to address the pandemic caused by SARS-CoV-2.
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Inapplicable
February 02, 2021
Lead Product(s) : UB-612
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Recipient : Vaxxinity
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : UB-612
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Sponsor : Vaxxinity
Deal Size : Inapplicable
Deal Type : Inapplicable
A Study to Evaluate the Safety, Tolerability, and Immunogenicity of UB-612 COVID-19 Vaccine
Details : Undisclosed
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Inapplicable
September 11, 2020
Lead Product(s) : UB-612
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Sponsor : Vaxxinity
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : UB-421
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : Taipei Veterans General Hospital | Kaohsiung Veterans General Hospital. | United Biomedical Inc., Asia
Deal Size : Inapplicable
Deal Type : Inapplicable
Study to Evaluate Safety and Efficacy of UB-421 Antibody in HIV-1 Infected Adults
Details : Undisclosed
Product Name : Undisclosed
Product Type : Antibody
Upfront Cash : Inapplicable
August 17, 2012
Lead Product(s) : UB-421
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : Taipei Veterans General Hospital | Kaohsiung Veterans General Hospital. | United Biomedical Inc., Asia
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : UB-421
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Study to Evaluate Safety and Pharmacokinetics of UB-421 Antibody in HIV-1 Infected Adults
Details : Undisclosed
Product Name : Undisclosed
Product Type : Antibody
Upfront Cash : Inapplicable
June 09, 2010
Lead Product(s) : UB-421
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable